NCT05653713View on ClinicalTrials.gov

Effects of CSL324 in the Lung After Segmental Challenge

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

July 21, 2023

Study Completion Date

July 21, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

CSL324

Single intravenous (IV) dose of CSL324

DRUG

Placebo

IV dose of 0.9% saline

Trial Locations (1)

30625

Fraunhofer Institute for Toxicology and Experimental Medicine, Hanover

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CSL Behring

INDUSTRY